Trial Profile
A Phase 1, Open-Label, Single-Dose, Randomized, 2-Period, 2-Treatment-Sequence Crossover Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary) ; Pacritinib (Primary)
- Indications Cancer; Chronic myeloid leukaemia; Graft-versus-host disease; Myelofibrosis
- Focus Pharmacokinetics
- Sponsors CTI BioPharma
- 24 Jun 2016 New trial record